News
-
-
COMMUNIQUÉ DE PRESSE
FatPipe (FATN) Announces General Availability of Total Security 360 Single-Stack Integrated Cybersecurity Platform with SD-WAN and Network Security for SMB Market
FatPipe, Inc. launches Total Security 360, a single-stack network, cybersecurity, and email security solution for simplified deployment. Features include SD-WAN, email sandboxing, integrated SIEM, resilient connectivity, and central control -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: BayWa AG: BayWa AG withdraws forecast for current fiscal year 2025 due to BayWa r.e. AG
BayWa AG withdraws forecast for fiscal year 2025 due to impact of changed regulatory framework on BayWa r.e. AG's EBITDA. Earnings forecasts deemed unreliable. Confidence in successful Group restructuring remains -
COMMUNIQUÉ DE PRESSE
Original-Research: Swissnet AG (formerly Beaconsmind AG) (von First Berlin Equity Research GmbH):
First Berlin Equity Research reaffirms BUY rating for Swissnet AG (formerly Beaconsmind AG) with EUR 19.00 price target, citing strong H1/25 results and international market expansion -
COMMUNIQUÉ DE PRESSE
Welcome to Monaco: The brand makes the market / Rock Capital Group continues to rate Munich, home to the EXPO REAL property trade fair, as one of the most exciting property markets in Germany.
Rock Capital Group rates Munich as one of the most exciting property markets in Germany, showcasing high demand and prime rents. Several flagship office projects in Munich underline the city's appeal and attract international tech firms -
COMMUNIQUÉ DE PRESSE
Rentschler Biopharma further expands its services in Japan and South Korea and will attend BioProcess International Asia
Rentschler Biopharma expands services in Japan and South Korea, showcasing innovative solutions at BioProcess International Asia conference. Strong strategic focus on client partnerships and market growth -
COMMUNIQUÉ DE PRESSE
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement -
